Kronos Historical Income Statement
| KRON Stock | USD 0.95 0.01 1.04% |
Historical analysis of Kronos Bio income statement accounts such as Interest Expense of 9.6 M can show how well Kronos Bio performed in making a profits. Evaluating Kronos Bio income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Kronos Bio's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Kronos Bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kronos Bio is a good buy for the upcoming year.
Kronos |
About Kronos Income Statement Analysis
Kronos Bio Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Kronos Bio shareholders. The income statement also shows Kronos investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Kronos Bio Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Kronos Bio. It is also known as Kronos Bio overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Kronos Bio's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Kronos Bio current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.At this time, Kronos Bio's Non Operating Income Net Other is very stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.7M | 2.3M | 9.2M | 9.6M | Depreciation And Amortization | 236.6K | 2.3M | 2.1M | 1.8M |
Kronos Bio income statement Correlations
Click cells to compare fundamentals
Kronos Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kronos Bio income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 699K | (3.0M) | 320K | 3.9M | 9.0M | 9.5M | |
| Depreciation And Amortization | 356K | 4.9M | 236.6K | 2.3M | 2.1M | 1.8M | |
| Interest Expense | 3K | 3.9M | 1.7M | 2.3M | 9.2M | 9.6M | |
| Selling General Administrative | 3.4M | 14.8M | 38.5M | 43.4M | 41.7M | 26.3M | |
| Other Operating Expenses | 16.8M | 58.0M | 151.4M | 137.1M | 128.1M | 91.3M | |
| Operating Income | (16.8M) | (58.0M) | (151.4M) | (137.1M) | (121.8M) | (127.9M) | |
| Net Income From Continuing Ops | (16.1M) | (88.4M) | (151.1M) | (133.2M) | (119.1M) | (125.1M) | |
| Ebit | (16.8M) | (84.6M) | (151.3M) | (137.1M) | (124.0M) | (130.2M) | |
| Research Development | 13.4M | 43.3M | 112.9M | 93.7M | 86.4M | 65.0M | |
| Ebitda | (16.5M) | (79.7M) | (151.1M) | (134.8M) | (121.8M) | (127.9M) | |
| Total Operating Expenses | 16.8M | 58.0M | 151.4M | 137.1M | 128.1M | 91.3M | |
| Reconciled Depreciation | 356K | 839K | 2.0M | 2.3M | 2.2M | 1.4M | |
| Income Before Tax | (16.1M) | (88.4M) | (151.1M) | (133.2M) | (112.7M) | (118.3M) | |
| Total Other Income Expense Net | 699K | (30.4M) | 320K | 3.9M | 9.2M | 9.6M | |
| Net Income Applicable To Common Shares | (16.1M) | (88.4M) | (151.1M) | (133.2M) | (119.9M) | (125.9M) | |
| Net Income | (15.4M) | (64.1M) | (149.1M) | (129.3M) | (112.7M) | (118.3M) |
Pair Trading with Kronos Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kronos Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kronos Bio will appreciate offsetting losses from the drop in the long position's value.Moving against Kronos Stock
| 0.71 | VTRS | Viatris | PairCorr |
| 0.65 | ESPR | Esperion Therapeutics | PairCorr |
| 0.65 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.65 | GILD | Gilead Sciences | PairCorr |
| 0.44 | EWTX | Edgewise Therapeutics | PairCorr |
The ability to find closely correlated positions to Kronos Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kronos Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kronos Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kronos Bio to buy it.
The correlation of Kronos Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kronos Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kronos Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kronos Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share 0.143 | Quarterly Revenue Growth 0.442 | Return On Assets (0.28) | Return On Equity (0.63) |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.